CD274 and neoplasm: Because PD-L1 protein expression changes dynamically during tumor progression, immunotherapy is affected by a variety of factors, including the PD-L1 expression level [11], mutational load [12], immune cell infiltration and function [13], immune checkpoint coexpression [14], and the gut microbiota [15].